Achillion pharmaceuticals inc (ACHN)
Income statement / Yearly
Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenue

-

-

15,000

66,122

-

-

2,607

247

2,436

-294

Operating expenses
Research and development

50,118

63,607

56,843

56,553

53,515

46,736

38,999

35,441

20,529

18,419

General and administrative

23,896

25,969

23,022

24,676

15,911

12,741

10,901

9,153

7,205

6,553

Restructuring charges (Note 4)

1,900

-

-

-

-

-

-

-

-

274

Total operating expenses

75,914

89,576

79,865

81,229

69,426

59,477

49,900

44,594

27,734

25,246

Loss from operations

-75,914

-89,576

-64,865

-15,107

-69,426

-59,477

-47,293

-44,347

-25,298

-25,540

Other income (expense)
Interest income

5,678

4,390

3,227

1,188

455

582

234

-

-

172

Interest income

-

-

-

-

-

-

-

186

-

-

Interest income

-

-

-

-

-

-

-

-

101

-

Interest expense

36

50

68

55

37

52

68

45

284

564

Other income

-

-

-

8,944

-

-

-

-

-

-

Net loss

-70,272

-85,236

-61,706

-5,030

-69,008

-58,947

-47,127

-44,206

-25,481

-25,932

Basic and diluted net loss per share (Note 5)

-0.51

-0.62

-0.45

-0.04

-0.70

-0.63

-0.64

-0.69

-0.57

-0.98

Unrealized income (loss) on marketable securities

190

-540

196

-

-

-

-

-

-

-

Unrealized income (loss) on marketable securities

-

-

-

-33

-18

-13

39

-

-

-

Unrealized (loss) gain on marketable securities

-

-

-

-

-

-

-

-22

2

-

Total other comprehensive income (loss)

190

-540

196

-33

-18

-13

39

-22

2

-

Total comprehensive loss (Note 9)

-70,082

-85,776

-61,510

-5,063

-69,026

-58,960

-47,088

-44,228

-25,479

-

Weighted average number of shares used in computing basic and diluted net loss per share

138,418

137,180

136,667

125,592

98,367

93,983

73,965

64,248

45,079

-

Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders

-

-

-

-

-

-

-

-

-

26,537